Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Wilson Therapeutics AB
Headquarters: Stockholm, Sweden
Website: N/A
Year Founded: 2012
Status: Acquired
BioCentury | Oct 29, 2024
Deals
Novartis adds another degrader, this time from Monte Rosa
Deals report: AbbVie acquires Aliada, Roche returns tau mAb to UCB, Monopar licenses AZ’s Wilson disease program, and more
BioCentury | Apr 27, 2023
Product Development
April 27 Quick Takes: AbbVie exits CF based on triplet’s readout
Plus: AZ cuts late-stage GLP-1, Wilson’s disease programs and updates from Sanofi, 4D Molecular, Generate
BioCentury | Mar 1, 2023
Management Tracks
C4’s Adam Crystal to head R&D at Tango
Plus: new CFO at BioArctic and updates from Sutro, Korro, BioAtla, Claris, Akoya and more
BioCentury | Nov 16, 2022
Management Tracks
Bungay becomes CEO at Imophoron, Garzoni transitions to CSO
Plus: Tracy named CTO at Code, and updates from ConcertAI, Lucy, Trevi and more
BioCentury | Dec 21, 2021
Product Development
Dec. 20 Quick Takes: Merck KGaA acquires neurology company Chord
Plus: Novavax gets EU nod, Moderna, Cytokinetics, Amgen and more
BioCentury | Aug 27, 2021
Deals
Aug. 26 Quick Takes: Bolt, Innovent partner on non-traditional antibody conjugates
Plus ADC royalty deal, Sobi, Servier, DiCE IPO plans, AZ in Wilson’s and more
BioCentury | Oct 13, 2020
Finance
Chord launches with $16M to test MS drug cladribine in rare autoimmune disorders
Omega Funds is sole investor for Swiss start-up’s series A, reuniting firm with CEO Plitz
BioCentury | May 5, 2020
Deals
Alexion sees opportunity in slow-selling Andexxa, buys Portola for $1.4B
A rare Alexion deal for a marketed product comes at a relative discount as Portola’s stock price has sunk
BioCentury | Oct 17, 2019
Company News
Deal streak continues for Alexion as Achillion’s story hits $930M high note
Items per page:
1 - 10 of 43